Krsnaa Diagnostics Q4 Results Review: Systematix Maintains 'Buy', Revises Target Price - Here's Why

Krsnaa remains confident around a recovery of the receivables based on their ongoing interaction with officials. Krsnaa’s track record on recovery of receivables so far remains clean with nothing lost on account of bad debts..NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Systematix Report.Krsnaa Diagnostics Ltd.’s Q4 FY25 revenue (Rs 1,861 million) was below our and consensus expectations but Ebitda (Rs 530 million) was inline. Revenue growth was lackluster (12% YoY). The pathology to radiology mix for the quarter stood at 50:50 and D2C contribution was 3.5% of revenue. Krsnaa expects D2C contribution to expand meaningfully in FY26 (5-8% of revenue). The radiology contribution is expected to increase as new centers open and ramp up. The revenue growth during the quarter was impacted by a slowdown in Himachal and Karnataka revenues owing to extended receivable days. Krsnaa remains confident around a recovery of the receivables based on their ongoing interaction with officials. Krsnaa’s track record on recovery of receivables so far remains clean with nothing lost on account of bad debts. We expect a ~20% revenue growth for Krsnaa for FY26 and FY27. Expansion in their D2C business and a resolution of receivable collection challenges should support business growth..We revise our estimates lower, but maintain our Buy rating on Krsnaa with a revised target price of Rs 879 based on 23 times FY27E earnings per share..Click on the attachment to read the full report:.Tata Motors Q4 Results Review: Motilal Oswal Maintains 'Neutral' On Multiple Headwinds, Lack Of Triggers.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Krsnaa Diagnostics Q4 Results Review: Systematix Maintains 'Buy', Revises Target Price - Here's Why

Receivables collection challenges impact Krsnaa's growth, adds Systematix.

NDTV Profit

NDTV Profit

Follow Us

DISCOVER US FASTER

DOWNLOAD THE APP